MMP1 Antibody (YA3703)

Matrix metalloproteinase-1 (MMP-1), also known as interstitial collagenase or collagenase-1, is a zinc-dependent extracellular matrix protease that cleaves fibrillar collagens, particularly types I, II, and III collagen^[1][2]. MMP-1 initiates collagenolysis by disrupting the triple-helical structure of collagen, enabling subsequent extracellular matrix remodeling during tissue repair and pathological processes^[2][3]. Mechanistically, MMP-1 activity is regulated at transcriptional and enzymatic levels, including control by signaling pathways such as AP-1-associated transcriptional regulation^[4]. In disease models, increased MMP-1 expression contributes to extracellular matrix degradation in rheumatoid arthritis, tumor invasion, metastasis, and other destructive tissue remodeling conditions^[1][4]. MMP-1 promotes keratinocyte migration by enabling movement across type I collagen matrices, demonstrating its role in wound repair models^[3]. Compared with related collagenases such as MMP-8 and MMP-13, MMP-1 is broadly expressed by multiple cell types and preferentially functions as an interstitial collagenase involved in degradation of stromal collagens^[1][2]. Unlike membrane-type MMPs such as MT1-MMP, MMP-1 is a secreted collagenase that primarily acts within extracellular matrix environments^[1][5]. For experimental applications, MMP-1 activity is commonly investigated using genetic regulation studies, collagen degradation assays, and pharmacological inhibition approaches with broad-spectrum or selective metalloproteinase inhibitors^[3][6]. MMP-1 inhibition strategies have been explored to study extracellular matrix remodeling mechanisms, although clinical translation of MMP inhibitors remains limited by specificity and safety challenges^[2].